Agony of choice-selecting chronic lymphocytic leukemia treatment in 2022.
Jan-Paul BohnPublished in: Memo (2022)
The treatment landscape of chronic lymphocytic leukemia (CLL) has undergone profound change in recent years. Targeted therapies have outnumbered chemotherapy-based treatment approaches demonstrating superior efficacy and tolerability profiles across nearly all CLL patient subgroups in the frontline and relapsed disease treatment setting. Individual selection of these novel agents is rather driven by patients' comorbidities and personal preferences than fitness and age. Given the high amount of currently licensed novel agents in both treatment-naïve as well as relapsed CLL patients and currently limited evidence from comparative clinical trials, clinicians sometimes appear spoilt for choice when selecting optimal therapy. This short review discusses recent clinical trial data focusing on treatment with targeted drugs and aims to help guide CLL treatment selection in individual patients.
Keyphrases
- clinical trial
- chronic lymphocytic leukemia
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- randomized controlled trial
- physical activity
- ejection fraction
- combination therapy
- squamous cell carcinoma
- drug delivery
- bone marrow
- autism spectrum disorder
- diffuse large b cell lymphoma
- body composition
- phase ii
- single cell
- peritoneal dialysis
- open label
- case report